NELDALEUCEL

UNII:	78SU4N7MVG
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	NELDALEUCEL
GSRS Full Record:	78SU4N7MVG i

Autologous multi (6) tumor-associated antigen (TAA)-specific T cell product that is specifically directed against the following six TAAs: preferentially expressed antigen in melanoma (PRAME), Wilms tumor 1 (WT1), New York esophageal 1 (NY-ESO-1), synovial sarcoma X breakpoint 2 (SSX2), melanoma-associated antigen A4 (MAGE-A4) and survivin
MT-601
MT-601 is an autologous multi-tumor associated antigen (TAA)-specific T cell immunotherapy product that depending on the patient’s endogenous precursors recognizes cancer cells expressing at least one of the 6 TAAs via native T cell receptors (TCRs), which interact with class I and II major histocompatibility complex (MHC also known as HLA [human leukocyte antigen]) presenting the antigenic peptides. The interaction between TCRs and the tumor antigen epitopes leads to T cell activation, proliferation, and acquisition of effector functions (e.g., secretion of inflammatory cytokines and/or chemokines and cytotoxicity). This sequence of events leads to killing of tumor cells expressing these antigens as well as the activation of other immune cells in the tumor microenvironment
NELDALEUCEL [USAN]
Neldaleucel

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

NELDALEUCEL

Synonyms and Mappings

Resources